ArticleCancer management and research2026
A Novel Prognostic Model Based on Prognostic Nutritional Index and Systemic Immune-Inflammation Index for Cancer Patients Treated with Immune Checkpoint Inhibitors.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The prognostic nutritional index (PNI) and systemic immune-inflammation index (SII) have both been reported as important indicators of prognosis in cancer patients. This study sought to construct and evaluate a combined PNI-SII score for predicting outcomes in patients undergoing immune checkpoint inhibitor (ICI) therapy. Methods: A total of 350 cancer patients treated with ICI-based therapy were retrospectively enrolled, with overall survival (OS) and progression-free survival (PFS) defined as the primary endpoints. The PNI-SII scoring model was developed as follows: score 0 (low SII and high PNI), score 1 (high SII or low PNI), score 2 (high SII and low PNI). Results: In the entire cohort, patients with high PNI level tended to have a significantly longer OS and PFS than those with low PNI level (both p<0.001), while the opposite was for patients with high SII level as compared with those with low SII level (OS, p<0.001; PFS, p=0.004). Consistently, the PNI-SII model was found to effectively stratify both OS and PFS in the entire cohort (both p<0.001), which was then confirmed in the subgroups stratified by cancer type, age, and smoking history. In addition, the PNI-SII score was associated with short-term treatment response and therapy-related adverse events. Conclusion: The PNI-SII model may serve as a convenient prognostic indicator for cancer patients receiving ICI therapy. Due to the limitations of the present study, further clinical investigations are necessary to validate its efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.